In addition, miR-101 improves the anti-tumor effect of sorafenib in HCC cells by targeting dual-specificity phosphatase 1 (DUSP1) and inhibiting TGF-β activation (Wei et al., 2015). This evidence concerns the gene TGFB1 and neoplasm.